Document:

March 31, 2009 10-Q EXHIBIT 10.2

Exhibit 10.2 

AMENDMENT NO. 3

to

ASSIGNMENT AGREEMENT

This AMENDMENT TO ASSIGNMENT AGREEMENT ("Amendment"), effective as
of March 30, 2009 (the "Amendment Date"), is made and entered into by and between PHARMACYCLICS,
INC., a Delaware corporation having a place of business at 995 East Arques Avenue, Sunnyvale, California 94085,
("Pharmacyclics") and CELERA CORPORATION having a place of business at 1401 Harbor Bay Parkway,
Alameda, California 94502 ("Celera").  Pharmacyclics and Celera may each be referred to herein individually as a
"Party" or, collectively, as "Parties."

WHEREAS, Applera Corporation, through its Celera Group, entered into an assignment agreement with
Pharmacyclics, effective as of April 7, 2006, whereby the Celera Group assigned to Pharmacyclics certain proprietary technology and
know-how related to the Celera Programs, including but not limited to the HDAC Program (the "Original Assignment
Agreement");

WHEREAS, Pharmacyclics and the Applera Corporation, through its Celera Group, subsequently executed
Amendment No. 1 to the Original Assignment Agreement, effective May 12, 2008, in order to amend certain payment terms of the
Assignment Agreement relating to [***] [***] (the "First Amendment");

WHEREAS, Pharmacyclics and Celera
Corporation, through its Celera Group, subsequently executed Amendment No. 2 to the Original Assignment Agreement, effective March 2,
2009, in order to amend certain payment terms of the Assignment Agreement relating to [***] [***] (the "Second
Amendment") (the Original Assignment Agreement, as amended by the First Amendment and the Second Amendment,
hereinafter the "Assignment Agreement"); 

WHEREAS, Pharmacyclics desires that certain terms of the Assignment Agreement should be amended;
and

WHEREAS, Celera desires that such terms should be amended, subject to the terms and conditions set
forth below.

NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth herein, and for
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Pharmacyclics and Celera hereby
agree as follows:

	In General.

All terms defined in the Assignment Agreement shall have a meaning in this Amendment as in the Assignment
Agreement, unless otherwise expressly defined in this Amendment.

	
*** 
	
Indicates that material has been omitted and confidential treatment has been requested, therefore all such omitted
material has been filed separately with the Commission pursuant to Rule 246-2.

	Amendment of the Assignment Agreement.

2.1   Payment by Pharmacyclics.  Pharmacyclics will pay to Celera $[***], due upon execution of this
Amendment. The foregoing payment will be fully creditable against any amounts otherwise payable by Pharmacyclics to Celera under the
Assignment Agreement.

2.2   Amendment of Section 6.5.  Section 6.5 of the Assignment Agreement is hereby amended
to read in its entirety as follows: 

6.5 Term of Royalties Payments. Pharmacyclics' obligation to pay Royalties under
Section 6.4 will continue, on an Assigned Product-by-Assigned Product basis, in each country of the world:

	In the case of any Assigned Product described in Section 1.5, Section 1.28 (except in the case of Assigned
Products described in Section 1.28(b)(iii)) and Section 1.35 (except in the case of Assigned Products described in Section 1.35(b)(iii))
for as long as the manufacture, use, sale, offer for sale or import of such Assigned Product is covered by a Celera Patent in the
country in which such Assigned Product is used or sold. 

	With respect to an Assigned Product that is an  [***] [***]  (including, without limitation, [***], any backup [***] and
[***]):

	Royalties will be due only when the sale of such [***]  [***]  is covered by a Valid Claim of a Celera Patent in the
country in which such product is sold; and

	If an [***]  [***]  is covered by  a Valid Claim of a Celera Patent in the country of sale, but if the product is
nonetheless subject to generic competition, then the royalty rate will be reduced from [***] % to [***] % with respect to sales in such country
[***] [***]and its territories. 

	In the case of any Assigned Product described in Section 1.28(b)(iii), for a period of [***] ([***]) years beginning
on the date of first commercial sale of such Assigned Product.

	Reference to and Effect on the Assignment Agreement.

3.1   Pursuant to Section 13.1 of the Assignment Agreement, this Amendment shall be effective upon the
Amendment Date, whereupon the Assignment Agreement shall be, and hereby is, amended as set forth herein.

3.2   On and after the Amendment Date, each reference in the Assignment Agreement to "this
Agreement," "hereunder," "hereof," "herein" or words of like import shall mean and be a reference to
the Assignment Agreement as amended hereby.  No reference to this Amendment need

	
*** 
	
Indicates that material has been omitted and confidential treatment has been requested, therefore all such omitted
material has been filed separately with the Commission pursuant to Rule 246-2.

                                                    2

be made in any instrument or document at any time
referring to the Assignment Agreement, a reference to the Assignment Agreement in any of such to be deemed to be a reference to the
Assignment Agreement as amended hereby.

3.3   All provisions of the Assignment Agreement not expressly modified by this Amendment shall remain in full force
and effect.

	Counterparts.

This Amendment may be executed in one or more counterparts, each of which shall be deemed to be an original,
but all of which together shall constitute a single instrument.

 

	
PHARMACYCLICS, INC.

 ("Pharmacyclics")

 

By: /s/ Robert W. Duggan

 Print Name: Robert W. Duggan

 Title: Chairman & CEO 
	 	
CELERA CORPORATION 

 ("Celera")

 

By: /s/ Kathy Ordonez

   Print Name:  Kathy Ordonez

 Title: CEO            

 

                                                    3 

	
*** 
	
Indicates that material has been omitted and confidential treatment has been requested, therefore all such omitted
material has been filed separately with the Commission pursuant to Rule 246-2.March 31, 2009 10-Q EXHIBIT 10.3

Exhibit 10.3 

AMENDMENT NO.1 TO LOAN AGREEMENT

AMENDMENT NO. 1 to LOAN AGREEMENT entered into as of March 31, 2009 (this "Amendment") by and
between Pharmacyclics, Inc., a Delaware corporation having a principal place of business at 995 E. Arques Avenue, Sunnyvale, CA
94085-4521 (the "Company"), and Robert W. Duggan & Associates (the "Lender") 

WHEREAS, on December 30, 2008, the Lender agreed to provide a loan to the Company in the principal amount of Five Million
Dollars ($5,000,000) (the "Initial Loan") pursuant to a loan agreement entered into as of December 30, 2008 by and
between the Company and the Lender (the "Initial Loan Agreement");

WHEREAS, the Lender has agreed to provide an additional loan to the Company in the amount of One Million Four Hundred
Thousand Dollars ($1,400,000) as financing pursuant to the terms hereof (the "Second Loan,", and together with the Initial
Loan, the "Loan");

WHEREAS, for purposes of inducing the Lender to make the Loan, the Company has agreed to issue a first amended and restated
unsecured promissory note to the Lender, all as more particularly described herein below;

WHEREAS, the Company and the Lender wish to amend and modify the Initial Loan Agreement upon the terms and conditions set
forth herein.

NOW, THEREFORE, in consideration of the premises, and the representations, warranties and agreements hereinbelow stated,
and for other good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as
follows:

1.Definitions.  All capitalized terms herein shall have the meanings ascribed to them in the Initial Loan Agreement,
unless otherwise defined herein.

2.Modifications of Initial Loan Agreement.  From and after the date hereof, the Initial Loan Agreement is hereby
modified and amended as follows:  

 1.1   The Loan.  As of December 30, 2008, the Lender made the Initial Loan and as of March 31, 2009, the Lender made
the Second Loan.  The Loan shall be evidenced by, and subject to the terms set forth in, a first amended and restated promissory note
dated March 31, 2009 in the form attached hereto as Exhibit A (the "Note") made by the Company in favor of the
Lender.

 1.2   Interest.  The Initial Loan shall bear interest of 1.36% from December 30, 2008 until March 31, 2009 and the Loan shall
bear interest as follows: (i) the rate of interest in effect for such day as publicly announced from time to time by Citibank N.A. as its
"prime rate" (the "Prime Rate") from April 1, 2009 until December 31, 2009 and (ii) the Prime Rate plus 2% from
January 1, 2010 until the expiration of the Note.  Interest shall be paid annually.

4.Full Force and Effect.  All terms, conditions and covenants contained in the Initial Loan Agreement shall remain in
full force and effect except as specifically amended herein.  The Initial Loan Agreement, as amended hereby is ratified and confirmed.

5.No Oral Changes.  This Amendment may not be changed, modified, discharged or terminated nor any of its
provisions waived orally, but only by an agreement in writing signed by the party against whom enforcement of any change,
modification, discharge, termination or waiver is sought.  From and after the date hereof, all references to the Loan Agreement in the
Note shall mean the Loan Agreement as modified pursuant to the terms of this Amendment.

6.Successors and Assigns.  This Amendment shall bind the Company and the successors and assigns of the
Company and shall bind and inure to the benefit of the Lender, and successors and assigns of Lender and all subsequent holders of
the Note.

7.Counterparts.  This Amendment may be executed in several counterparts, each of which shall constitute an original,
and all of which, when taken together, shall constitute but one instrument.

                                                    2

IN WITNESS WHEREOF, the undersigned have executed this First Amendment to Loan Agreement on the date above first
written.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first set forth above.

	
PHARMACYCLICS, INC.
	 	
ROBERT W. DUGGAN & ASSOCIATES

	
995 E. Arques Avenue

Sunnyvale, California  94085-4521
	 	
1933 Cliff Drive, Suite 30

Santa Barbara, California 93107

	 	 	 
	
By: 
	/s/ GLENN C. RICE
	 	
By: 
	/s/ EOBERT W. DUGGAN

	 	
Name:
	
Glenn C. Rice, Ph.D. 
	 	 	
Name:
	
Robert W. Duggan

	 	
Title:
	
President, Chief Operating Officer and Director
	 	 	
Title:
	
Principal

                                                    3

Exhibit A

March 31, 2009

Pharmacyclics, Inc.

First Amended and Restated Unsecured Promissory Note

$6,400,000

This FIRST AMENDED AND RESTATED UNSECURED PROMISORY NOTE is made as of the 31st day of
March, 2009 by and between Pharmacyclics, a Delaware corporation (the "Company"), and Robert W. Duggan &
Associates (the "Lender"), or its successors and assigns.

RECITALS:

A.Lender made a loan (the "Initial Loan") to the Company evidenced by a certain Unsecured Promissory Note
dated December 30, 2008, (the "Note"), in the original principal amount of Five Million Dollars ($5,000,000) made by the
Company for the benefit of Lender.  

B.The Company and the Lender wish to amend and restate the Note upon the terms and conditions set forth herein, and the
original Note is hereby cancelled.

NOW, THEREFORE, FOR VALUE RECEIVED, the Company hereby promises to pay to Lender, or its successors and assigns, the
principal amount of Six Million Four Hundred Thousand Dollars ($6,400,000), together with interest computed in accordance with the
terms of this Note below (the "Loan"), on or before the earlier of (i) July 1, 2010 or (ii) upon the closing of the Offering (the
"Maturity Date"), provided that the note shall only accelerate up to the amount of net proceeds raised in the Offering.

This Note is given pursuant to that certain Loan Agreement, dated December 30, 2008, as amended on March 31, 2009, (the
"Loan Agreement"), by and between the Company and the Lender, and is entitled to the benefits of the Loan Agreement.
The Loan Agreement provides, among other things, (i) for the making of the Loan by the Lender to the Company in the aggregate
amount of $6,400,000, the indebtedness of the Company evidenced by this Note, and (ii) for Events of Default, and for acceleration of
the maturity of the unpaid principal amount of this Note upon the happening of certain stated events and also for prepayments on
account of the principal hereof prior to the maturity hereof upon the terms and conditions therein specified.  Defined terms used and not
otherwise defined herein have the same meanings given such terms in the Loan Agreement.

	 Payments, Replacement of Note.

1.1   Payment of Principal and Interest.  Interest and principal on this Note shall be payable by the Company on an annual basis by
wire transfer of funds or by mailing a check by overnight courier service to the Lender at such address as the Lender may notify the
Company in writing from time to time.  Payments of principal and interest and amounts due with respect to costs and expenses
pursuant to the Loan Agreement, shall be made in lawful money of the

                                                    A-1

United States of America in immediately available funds, without
deduction, set-off or counterclaim to the Lender.  The Company waives grace, demand, presentment for payment, notice of dishonor or
default, protest, notice of protest, notice of intent to accelerate, notice of collection, notice of acceleration and diligence in collecting and
bringing of suit.

1.2   Interest.  The Initial Loan shall bear interest as a rate per annum of 1.36% from December 30, 2008 until March 31, 2009
and the Loan shall bear interest at a rate per annum of (i) the rate of interest in effect for such day as publicly announced from time to
time by Citibank N.A. as its "prime rate" (the "Prime Rate") from April 1, 2009 until December 31, 2009 and (ii)
the Prime Rate plus 2% from January 1, 2010 until the expiration of the Note.  Interest shall be calculated on the actual number of days
elapsed over a 360-day year, on the unpaid principal balance hereof, until paid in full.

1.3   Prepayment.  The Company, at its election, may from time to time prepay without penalty all or any part of the unpaid
balance of this Note prior to the Maturity Date.  All payments made pursuant to this Section l.3 will be first applied to accrued interest, if
any, and the balance, if any, to principal.

1.4   Lost or Destroyed Note.  Upon receipt of evidence satisfactory to the Company that this Note has been mutilated,
destroyed or lost, and upon proof of ownership and receipt of indemnity from the Lender satisfactory in the form and amount to the
Company, the Company shall execute and deliver a new Note stated to mature on the same date and for the same principal amount as
this Note so mutilated, destroyed or lost, of like tenor with such notations, if any, as the Company shall reasonably determine, upon
surrender and cancellation of, and in exchange and substitution for, such mutilated Note, or in lieu of and in substitution for this Note so
destroyed or lost.

	Miscellaneous.

2.1   Successors and Assigns.  All covenants, agreements and undertakings in this Note by and on behalf of any of the parties
hereto shall inure to the benefit of and be binding upon the respective heirs, administrators, personal representatives, successors and
assigns of the parties hereto.  The Lender may assign its rights under this Note and the other Loan Documents.

2.2   Amendments and Waivers.  No changes in or additions to this Note may be made or compliance with any term, covenant,
agreement, condition or provision set forth herein may be omitted or waived (either generally or in a particular instance and either
retroactively or prospectively) without the written consent of the Lender.

2.3   Governing Law.  This Note and the other Loan Documents shall be governed by and construed in accordance with the
laws of the State of New York, without regard to any conflict of law provisions.  The Company agrees to the exclusive jurisdiction and
venue of the state and federal courts located in New York, New York to resolve any dispute arising under or related in any manner to
this Note.

[Signature Page Follows]

                                                    A-2

IN WITNESS WHEREOF, the Company has caused this Note to be duly executed on the date hereof.

	
PHARMACYCLICS, INC.
	 	 
	 	 	 
	 	 	 
	
By: 
	/s/ GLENN C. RICE
	 	 	 
	 	
Name:
	
Glenn C. Rice, Ph.D.
	 	 	 	 
	 	
Title:
	
President, Chief Operating Officer and Director
	 	 	 	 

                                                    A-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]